by McKesson Ventures | Apr 6, 2020 | Media Coverage
McKesson’s Sarah Alwardt, Ph.D, recently wrote in OncLive about the importance of real-world evidence (RWE) in the field of cancer treatment research. Fewer than 5 percent of adults with cancer enroll in clinical trials, but sufficient enrollment is necessary in order...
by McKesson Ventures | Mar 31, 2020 | Portfolio News
GRAIL today announced that validation data for its multi-cancer early detection blood test were published in Annals of Oncology. These data show that GRAIL’s technology can detect more than 50 cancer types across all stages, with a false positive rate of less than 1%,...
by McKesson Ventures | Mar 31, 2020 | Portfolio News
While the Bay Area shelters in place, people are increasingly turning to telemedicine to have their COVID-19 concerns and other issues addressed by doctors. Doctors say telehealth should be the default right now, although if necessary, patients can visit a doctor or...
by McKesson Ventures | Mar 31, 2020 | Portfolio News
Telemedicine promised to make health care more accessible without the need to wait at doctor’s offices. However, up until the beginning of the COVID-19 pandemic, few people used such services. Now services are being overloaded and waits have increased to hours....
by McKesson Ventures | Mar 30, 2020 | Portfolio News, Press Releases
Health system Providence is now remotely monitoring COVID-19 patients using the Xealth digital platform to deliver Twistle’s care automation and remote patient monitoring platform. Providence is using a solution from Twistle to reach out automatically to at-risk...
